D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.47% |
| 2 | Consumer Discretionary | 13.31% |
| 3 | Healthcare | 13.17% |
| 4 | Financials | 7.14% |
| 5 | Industrials | 6.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
Criteo S.A. Ordinary Shares
CRTO
$1.1B
| $1.74M | ﹤0.01% |
86,976
-35,093
| -29% | -$894K |
|
2202
PUT
C.H. Robinson
CHRW
$17.4B
| $1.74M | ﹤0.01% |
20,000
| – | – |
|
2203
Angi Inc
ANGI
$229M
| $1.74M | ﹤0.01% |
11,247
-8,023
| -42% | -$1.3M |
|
2204
UNIFI
UFI
$119M
| $1.74M | ﹤0.01% |
89,744
+53,681
| +149% | +$1.17M |
|
|
CLVS
2205
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.74M | ﹤0.01% |
70,000
-152,400
| -69% | -$3.82M |
|
|
GRMN
2206
CALL
Garmin
GRMN
$56.7B
| $1.74M | ﹤0.01% |
+20,100
| New | +$1.51M |
|
2207
Hanover Insurance
THG
$8.1B
| $1.74M | ﹤0.01% |
15,197
-17,023
| -53% | -$1.96M |
|
|
SWIR
2208
DELISTED
Sierra Wireless
SWIR
| $1.74M | ﹤0.01% |
140,255
+104,766
| +295% | +$1.44M |
|
2209
CALL
NetApp
NTAP
$35B
| $1.73M | ﹤0.01% |
25,000
| – | – |
|
2210
PUT
Fluor
FLR
$7.01B
| $1.73M | ﹤0.01% |
47,100
+35,200
| +296% | +$1.29M |
|
2211
LGI Homes
LGIH
$1.27B
| $1.73M | ﹤0.01% |
+28,745
| New | +$1.66M |
|
2212
Sempra
SRE
$57.9B
| $1.73M | ﹤0.01% |
27,518
-87,620
| -76% | -$5.16M |
|
|
VRAY
2213
DELISTED
ViewRay, Inc.
VRAY
| $1.73M | ﹤0.01% |
+234,359
| New | +$1.81M |
|
2214
CALL
Madrigal Pharmaceuticals
MDGL
$10.8B
| $1.73M | ﹤0.01% |
13,800
| – | – |
|
2215
Duluth Holdings
DLTH
$155M
| $1.73M | ﹤0.01% |
72,504
+19,035
| +36% | +$452K |
|
|
CMRX
2216
DELISTED
Chimerix, Inc.
CMRX
| $1.73M | ﹤0.01% |
822,695
+163,401
| +25% | +$372K |
|
|
WWE
2217
DELISTED
World Wrestling Entertainment
WWE
| $1.73M | ﹤0.01% |
19,903
+16,103
| +424% | +$1.36M |
|
|
CYBR
2218
PUT
DELISTED
CyberArk
CYBR
| $1.73M | ﹤0.01% |
+14,500
| New | +$1.39M |
|
|
CSOD
2219
CALL
DELISTED
Cornerstone OnDemand, Inc.
CSOD
| $1.73M | ﹤0.01% |
31,500
-10,000
| -24% | -$553K |
|
2220
CALL
Zimmer Biomet
ZBH
$18.2B
| $1.72M | ﹤0.01% |
+13,905
| New | +$1.58M |
|
2221
Clean Energy Fuels
CLNE
$427M
| $1.72M | ﹤0.01% |
557,499
+101,486
| +22% | +$226K |
|
2222
Elevance Health
ELV
$81.5B
| $1.72M | ﹤0.01% |
5,995
-15,605
| -72% | -$4.51M |
|
2223
Kiniksa Pharmaceuticals
KNSA
$5.8B
| $1.72M | ﹤0.01% |
95,256
+85,714
| +898% | +$1.66M |
|
2224
Aflac
AFL
$64.9B
| $1.72M | ﹤0.01% |
34,341
-22,494
| -40% | -$1.08M |
|
2225
CALL
Wolfspeed
WOLF
$1.23B
| $1.72M | ﹤0.01% |
30,000
-2,400
| -7% | -$123K |
|
Similar funds
D.E. Shaw & Co's Q1 2019 Portfolio in Review
As of Q1 2019, D.E. Shaw & Co held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
D.E. Shaw & Co withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, D.E. Shaw & Co opened a new position in Lyft worth $159M.
- D.E. Shaw & Co's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- D.E. Shaw & Co added most to Pfizer in Q1 2019, an estimated $436M increase.
- D.E. Shaw & Co's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- D.E. Shaw & Co fully exited Shire pic in Q1 2019, selling an estimated $276M.
- D.E. Shaw & Co's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- D.E. Shaw & Co opened 447 new positions and closed 617 in Q1 2019.
- D.E. Shaw & Co's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.